Dosing & Uses
Dosage Forms & Strengths
intravenous solution
- 0.4mg/5mL
Pharmacologic Stress Agent
Indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress
5 mL (0.4 mg) IVP
Administration
Administer as rapid (~10 sec) injection into a peripheral vein using 22 gauge or larger catheter or needle
Inspect visually, prior to admin, DO NOT administer if discolored or particulate matter present
Administer 5 mL saline flush, immediately after
Administer radionuclide myocardial perfusion imaging agent 10-20 sec after saline flush
- Radionuclide may be injected directly into same catheter as regadenoson
Renal Impairment
No dose adjustment needed in renal impairment including patients end stage renal disease and/or dependent on dialysis
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (3)
- caffeine
caffeine decreases effects of regadenoson by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid methylxanthines for 12 hours before regadenoson administration.
- dipyridamole
dipyridamole, regadenoson. Mechanism: unspecified interaction mechanism. Contraindicated. Regadenoson's effects may be changed; mfr. recommends avoiding dipyridamole for 2 days prior to administration.
- theophylline
theophylline decreases effects of regadenoson by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid methylxanthines for 12 hours before regadenoson administration.
Monitor Closely (0)
Minor (0)
Adverse Effects
>10%
Dyspnea (28%)
Headache (26%)
Rhythm conduction abnormalities (26%)
Flushing (16%)
PVCs (14%)
Chest Discomfort (13%)
Angina or ST segment depression (12%)
1-10%
Dizziness (8%)
Chest pain (7%)
PACs (7%)
Nausea (6%)
Ventricular conduction abnormalities (6%)
Abdominal discomfort (5%)
Dysgeusia (5%)
Feeling hot (5%)
First-degree AV block (3%)
<1%
Anaphylaxis, angioedema, cardiac arrest, respiratory arrest/distress, throat tightness, and urticaria/rashes, atrial fibrillation, seizures, cardiovascular accidents (stroke)
Postmarketing reports
Cardiovascular: Myocardial infarction, cardiac arrest, ventricular arrhythmias, supraventricular tachyarrhythmias including atrial fibrillation with rapid ventricular response (new-onset or recurrent), atrial flutter, heart block (including third-degree block), asystole, marked hypertension, symptomatic hypotension in association with transient ischemic attack, seizures and syncope
Central nervous system: Tremor, seizure, transient ischemic attack, and cerebrovascular accident including intracranial hemorrhage
Warnings
Contraindications
Second- or third-degree AV block, or sinus node dysfunction (unless patient has a functioning artificial pacemaker installed)
Cautions
Appropriate bronchodilator therapy and resuscitative measures should be available prior to and following therapy; adhere to recommended duration of injection; longer injection times may increase duration and magnitude of increase in coronary blood flow
QT prolongation has occurred shortly after administration in postmarketing surveillance
Adenosine receptor agonists can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention
Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, and rashes have occurred
Adenosine receptor agonists may cause dyspnea, bronchoconstriction, and respiratory compromise; caution with asthma or bronchoconstrictive disease; appropriate bronchodilator therapy and resuscitative measures should be available prior to and following therapy administration
Nucleoside transport inhibitors (eg, dipyridamole) and potentiate the vasoactive effects of regadenoson; withhold for 5 half-lives before regadenoson administration
Methylxanthines (eg, caffeine, theophylline) are adenosine receptor antagonists and inhibit regadenoson’s vasoactive effects; withhold methylxanthines for 5 half-lives before regadenoson administration
Aminophylline may increase risk of seizures associated with regadenoson injection; aminophylline may increase risk of seizures associated with therapy; methylxanthine use is not recommended in patients who experience a seizure in association with this drug
May lower seizure threshold; new-onset or recurrence of convulsive seizures has occurred following regadenoson injection; some seizures are prolonged and require emergent anticonvulsive management
Hemorrhagic and ischemic cerebrovascular accidents have occurred; effects of including hypotension or hypertension may be associated with these adverse reactions
New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter reported
Adenosine receptor agonists induce arterial vasodilation and hypotension; risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency; in post-marketing experience, syncope, transient ischemic attacks and seizures have been observed
Administration of adenosine receptor agonists may result in clinically significant increases in blood pressure in some patients; in post-marketing experience, cases of potentially clinically significant hypertension have been reported, particularly with underlying hypertension and when low-level exercise was included in the myocardial perfusion imaging
Myocardial ischemia
- Fatal and nonfatal myocardial infarction (MI), ventricular arrhythmias, and cardiac arrest reported; avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reaction
- Cardiac resuscitation equipment and trained staff should be available before administering therapy; adhere to recommended duration of injection; as noted in an animal study, longer injection times may increase duration and magnitude of increase in coronary blood flow
- If serious reactions occur, consider use of aminophylline, an adenosine antagonist, to shorten duration of increased coronary blood flow induced by the drug
Risk for myocardial infarction and death
- Avoid use for cardiac nuclear stress tests in patients with signs or symptoms of acute myocardial ischemia (eg, unstable angina, cardiovascular instability); use may increase risk of fatal MI
- Screen all nuclear stress test candidates for risks
Pregnancy & Lactation
Pregnancy
There are no available data on use in pregnant women to inform a drug-associated risk
Animal data
- In animal reproduction studies, adverse developmental outcomes were observed with the administration to pregnant rats and rabbits during organogenesis only at doses that produced maternal toxicity
Lactation
There is no information on presence of regadenoson in human milk, effects on breastfed infant, or on milk production; because of the potential risk of serious cardiac reactions in breastfed infant, advise the nursing mother to pump and discard breast milk for 10 hours after administration of the drug
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Low affinity agonist for the A2A adenosine receptor
Activation of the A2A adenosine receptor produces coronary vasodilation and increases coronary blood flow
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Lexiscan intravenous - | 0.4 mg/5 mL solution | ![]() | |
regadenoson intravenous - | 0.4 mg/5 mL solution | ![]() | |
regadenoson intravenous - | 0.4 mg/5 mL solution | ![]() | |
regadenoson intravenous - | 0.4 mg/5 mL solution | ![]() |
Copyright © 2010 First DataBank, Inc.
Patient Handout
regadenoson intravenous
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.